Eiken Chemical Of Japan Aims To Become Global Testing Agent Maker With ¥30 Billion In Sales
This article was originally published in PharmAsia News
Executive Summary
Japanese diagnostic and testing agent maker Eiken Chemical announced April 28 plans to achieve ¥30 billion in sales in three to four years, and increase overseas sales from current 5 percent to 10 percent. For fiscal year 2009, the company estimated 2.6 percent increase in sales, reaching ¥26.7 billion. Eiken plans to expand markets for major products such as fecal occult blood and bacterial testing agents, urine testing paper, and develop new products based on loop-mediated isothermal amplification methods. Two such new products, Legionella and Mycoplasma pneumonia testing agents are under approval review in Japan. The company plans to launch them in September. In overseas market, Eiken unveiled an ambitious goal of ¥1.8 billion in sales for 2009, a 21 percent increase. (Click here for more - Japanese language
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.